Harmony Biosciences Holdings, Inc.HRMY

Is HRMY cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$41.52+0.42 (+1.02%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$2B
Mid-cap
+4%
2020 — today
10-Year Price
+11%
2020 — today
52-Week Range
$25.90$42.86
Current $41.52· 92%

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Similar companies

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
13.5
Around average
Around the 10-year average
Sector median 24.7below sector
P/B ratio
2.4
Historically cheap
Historically cheap relative to the last 10 years
Sector median 2.5in line with sector
EV / EBITDA
7.4
Below average
Below the 10-year average
Sector median 15.2below sector
PEG ratio
0.2
Near historic high
Near historic highs — last 10 years
Sector median 1.5below sector
FCF Yield
14.5%
Historically high
Historically high relative to the last 10 years
Sector median -9.6%above sector
Free · No credit card needed

Get alerted when HRMY is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.